Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ALNTTRSC-04 by Alnylam Pharmaceuticals for Amyloidosis: Likelihood of Approval
ALNTTRSC-04 is under clinical development by Alnylam Pharmaceuticals and currently in Phase I for Amyloidosis. According to GlobalData, Phase I...